vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and PAMT CORP (PAMT). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $141.3M, roughly 1.7× PAMT CORP). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -20.7%, a 31.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -15.1%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-25.0M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -12.0%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ANIP vs PAMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $141.3M |
| Net Profit | $27.5M | $-29.3M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | -27.0% |
| Net Margin | 11.1% | -20.7% |
| Revenue YoY | 29.6% | -15.1% |
| Net Profit YoY | 367.5% | 7.4% |
| EPS (diluted) | $1.14 | $-1.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $141.3M | ||
| Q3 25 | $227.8M | $150.3M | ||
| Q2 25 | $211.4M | $151.1M | ||
| Q1 25 | $197.1M | $155.3M | ||
| Q4 24 | $190.6M | $166.5M | ||
| Q3 24 | $148.3M | $182.6M | ||
| Q2 24 | $138.0M | $182.9M | ||
| Q1 24 | $137.4M | $182.6M |
| Q4 25 | $27.5M | $-29.3M | ||
| Q3 25 | $26.6M | $-5.6M | ||
| Q2 25 | $8.5M | $-9.6M | ||
| Q1 25 | $15.7M | $-8.1M | ||
| Q4 24 | $-10.3M | $-31.6M | ||
| Q3 24 | $-24.2M | $2.4M | ||
| Q2 24 | $-2.3M | $-2.9M | ||
| Q1 24 | $18.2M | $281.0K |
| Q4 25 | 14.1% | -27.0% | ||
| Q3 25 | 15.9% | -3.8% | ||
| Q2 25 | 6.6% | -7.3% | ||
| Q1 25 | 13.3% | -5.9% | ||
| Q4 24 | -2.3% | -22.6% | ||
| Q3 24 | -13.8% | 1.3% | ||
| Q2 24 | 3.7% | -0.4% | ||
| Q1 24 | 14.8% | -0.4% |
| Q4 25 | 11.1% | -20.7% | ||
| Q3 25 | 11.7% | -3.7% | ||
| Q2 25 | 4.0% | -6.4% | ||
| Q1 25 | 8.0% | -5.2% | ||
| Q4 24 | -5.4% | -19.0% | ||
| Q3 24 | -16.3% | 1.3% | ||
| Q2 24 | -1.7% | -1.6% | ||
| Q1 24 | 13.2% | 0.2% |
| Q4 25 | $1.14 | $-1.38 | ||
| Q3 25 | $1.13 | $-0.27 | ||
| Q2 25 | $0.36 | $-0.46 | ||
| Q1 25 | $0.69 | $-0.37 | ||
| Q4 24 | $-0.45 | $-1.44 | ||
| Q3 24 | $-1.27 | $0.11 | ||
| Q2 24 | $-0.14 | $-0.13 | ||
| Q1 24 | $0.82 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $83.7M |
| Total DebtLower is stronger | — | $333.9M |
| Stockholders' EquityBook value | $540.7M | $210.5M |
| Total Assets | $1.4B | $697.9M |
| Debt / EquityLower = less leverage | — | 1.59× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $83.7M | ||
| Q3 25 | $262.6M | $115.6M | ||
| Q2 25 | $217.8M | $117.3M | ||
| Q1 25 | $149.8M | $102.7M | ||
| Q4 24 | $144.9M | $110.7M | ||
| Q3 24 | $145.0M | $92.3M | ||
| Q2 24 | $240.1M | $114.0M | ||
| Q1 24 | $228.6M | $125.8M |
| Q4 25 | — | $333.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $325.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $210.5M | ||
| Q3 25 | $505.8M | $239.5M | ||
| Q2 25 | $436.8M | $244.9M | ||
| Q1 25 | $418.6M | $269.6M | ||
| Q4 24 | $403.7M | $277.5M | ||
| Q3 24 | $405.9M | $308.9M | ||
| Q2 24 | $455.8M | $306.7M | ||
| Q1 24 | $452.0M | $314.6M |
| Q4 25 | $1.4B | $697.9M | ||
| Q3 25 | $1.4B | $715.2M | ||
| Q2 25 | $1.3B | $707.9M | ||
| Q1 25 | $1.3B | $712.6M | ||
| Q4 24 | $1.3B | $741.7M | ||
| Q3 24 | $1.3B | $756.7M | ||
| Q2 24 | $920.8M | $733.5M | ||
| Q1 24 | $914.5M | $746.4M |
| Q4 25 | — | 1.59× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-5.8M |
| Free Cash FlowOCF − Capex | $29.1M | $-25.0M |
| FCF MarginFCF / Revenue | 11.8% | -17.7% |
| Capex IntensityCapex / Revenue | 0.5% | 13.6% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-23.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-5.8M | ||
| Q3 25 | $44.1M | $5.9M | ||
| Q2 25 | $75.8M | $12.2M | ||
| Q1 25 | $35.0M | $5.0M | ||
| Q4 24 | $15.9M | $15.2M | ||
| Q3 24 | $12.5M | $15.5M | ||
| Q2 24 | $17.4M | $18.7M | ||
| Q1 24 | $18.3M | $9.6M |
| Q4 25 | $29.1M | $-25.0M | ||
| Q3 25 | $38.0M | $2.5M | ||
| Q2 25 | $71.8M | $5.9M | ||
| Q1 25 | $32.5M | $-6.8M | ||
| Q4 24 | $13.5M | $-39.9M | ||
| Q3 24 | $7.7M | $-33.6M | ||
| Q2 24 | $13.0M | $4.1M | ||
| Q1 24 | $13.7M | $-12.2M |
| Q4 25 | 11.8% | -17.7% | ||
| Q3 25 | 16.7% | 1.7% | ||
| Q2 25 | 34.0% | 3.9% | ||
| Q1 25 | 16.5% | -4.4% | ||
| Q4 24 | 7.1% | -24.0% | ||
| Q3 24 | 5.2% | -18.4% | ||
| Q2 24 | 9.4% | 2.2% | ||
| Q1 24 | 10.0% | -6.7% |
| Q4 25 | 0.5% | 13.6% | ||
| Q3 25 | 2.7% | 2.3% | ||
| Q2 25 | 1.9% | 4.2% | ||
| Q1 25 | 1.3% | 7.6% | ||
| Q4 24 | 1.3% | 33.1% | ||
| Q3 24 | 3.2% | 26.9% | ||
| Q2 24 | 3.2% | 8.0% | ||
| Q1 24 | 3.3% | 12.0% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.44× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | 34.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
